









Markets
/
Stocks
/
nasdaq-ints
/

Intensity Therapeutics Inc

INTS

0.575USD

+0.040+7.50%

Market hours （ET）Quotes delayed by 15 min

15.05MMarket Cap

LossP/E TTM



Intensity Therapeutics Inc

0.575

+0.040+7.50%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Intensity Therapeutics Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Intensity Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

280 / 501

Overall Ranking

505 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Buy

Current Rating

2.500

Target Price

+303.23%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Intensity Therapeutics Inc Highlights

StrengthsRisks

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. The Company is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead investigational product candidate, INT230-6, is designed for direct intratumoral injection. Its INT230-6 is primarily comprised of three components: cisplatin, vinblastine sulfate and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of Phase III open-label, randomized study testing the superiority of INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, and Phase II/III clinical study in metastatic triple negative breast cancer.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -0.30, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 2.00M shares, decreasing 26.44% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 40.59K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 5.17.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Intensity Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 6.12, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -0.30, which is -12.20% below the recent high of -0.26 and -691.44% above the recent low of -2.37.

Score

Industry at a Glance

Previous score

6.12

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 280/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 7.60, which is lower than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Intensity Therapeutics Inc is 3.00, with a high of 5.00 and a low of 1.50.

Score

Industry at a Glance

Previous score

7.60

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Buy

Current Rating

2.500

Target Price

+367.29%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Intensity Therapeutics Inc

INTS

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 4.99, which is lower than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 0.34 and the support level at 0.19, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.93

Change

0.06

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.087

Buy

RSI(14)

54.540

Neutral

STOCH(KDJ)(9,3,3)

28.586

Sell

ATR(14)

0.187

High Vlolatility

CCI(14)

40.347

Neutral

Williams %R

79.485

Sell

TRIX(12,20)

4.215

Buy

StochRSI(14)

7.759

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

0.694

Sell

MA10

0.468

Buy

MA20

0.375

Buy

MA50

0.308

Buy

MA100

0.305

Buy

MA200

0.934

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 4.07%, representing a quarter-over-quarter decrease of 79.05%. The largest institutional shareholder is The Vanguard, holding a total of 40.59K shares, representing 0.08% of shares outstanding, with 94.01% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Batterson (Leonard A.)

2.45M

Bender (Lewis H)

2.02M

Duchossois (Craig J)

976.80K

-3.36%

Sapient Capital LLC

976.80K

LFP Management LLC

696.87K

Sentinus, LLC

199.32K

+629.99%

Brown Advisory

130.07K

Mesirow Financial Investment Management, Inc.

110.00K

+175.00%

Wesolowski (John M CPA)

76.44K

Geode Capital Management, L.L.C.

72.81K

-6.03%

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.